Obesity is now the most common nutritional disorder in western
industrialized countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body fro
August 31, 2006 (Press Release) --
Obesity is now the most common nutritional disorder in western
industrialized countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from over consumption of fatty foods. Prevalence of obesity in the US and Europe has reached epidemic levels.
While obesity reaches epidemic proportions, the afflicted become increasingly desperate to find ways to control body weight. Too much hype and misinformation abounds concerning weight loss. Almost all diet pills, programs, behavior changes and potions fail in the long run. Exercise and a balanced diet is the best way to loose weight. Nevertheless diet pills are very tempting if one is disinclined to exercise or do not have the time to do so. The worthiness of diet pills have been proved by the plethora of brands available in the market and the success of most of them.
Most brands of prescription diet pills, like Adipex, Bontril. Didrex, Ionamin, Phentermine and Tenuate work by reducing appetite. They stimulate the brain and nerves, which increases heart rate and blood pressure and typically decreases appetite. These diet pills are for short term use. One must remember weight lossdrugs are effective when combined with diet and exercise.
The latest addition to the list of diet pills is Acomplia and in less than a month since it was introduced it has created waves all over Europe. Tipped as a future multibillion-dollar-a-year seller, Acomplia is all set to surprise the weight loss drug market. Acomplia has dual advantage attached to it property since it can help people both lose weight and quit smoking. Developed by Sanofi-Aventis, Acomplia (rimonabant) is a Endocannabinoid receptor antagonist indicated for the treatment of obesity. It was first introduced in the United Kingdom, and lately all over Europe. Since the introduction of Fen-Phen no drug has generated so much of excitement as Acomplia. Millions of obese have eagerly waited for this miracle drug.
The drug is expected to be marketed in the United States, under the name Zimulti. Whatever the trade name, rimonabant has been hailed by some doctors on the basis of clinical trials as a major breakthrough in treating obesity.
The success of Acomplia would depend on the quantum of side effects. The established anti-obesity drugs like Xenical, Meridia (Reductil in Europe), Didrex, and, Phentermine, however, have proven to have troublesome side effects, disappointing millions of dieters.
industrialized countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from over consumption of fatty foods. Prevalence of obesity in the US and Europe has reached epidemic levels.
While obesity reaches epidemic proportions, the afflicted become increasingly desperate to find ways to control body weight. Too much hype and misinformation abounds concerning weight loss. Almost all diet pills, programs, behavior changes and potions fail in the long run. Exercise and a balanced diet is the best way to loose weight. Nevertheless diet pills are very tempting if one is disinclined to exercise or do not have the time to do so. The worthiness of diet pills have been proved by the plethora of brands available in the market and the success of most of them.
Most brands of prescription diet pills, like Adipex, Bontril. Didrex, Ionamin, Phentermine and Tenuate work by reducing appetite. They stimulate the brain and nerves, which increases heart rate and blood pressure and typically decreases appetite. These diet pills are for short term use. One must remember weight lossdrugs are effective when combined with diet and exercise.
The latest addition to the list of diet pills is Acomplia and in less than a month since it was introduced it has created waves all over Europe. Tipped as a future multibillion-dollar-a-year seller, Acomplia is all set to surprise the weight loss drug market. Acomplia has dual advantage attached to it property since it can help people both lose weight and quit smoking. Developed by Sanofi-Aventis, Acomplia (rimonabant) is a Endocannabinoid receptor antagonist indicated for the treatment of obesity. It was first introduced in the United Kingdom, and lately all over Europe. Since the introduction of Fen-Phen no drug has generated so much of excitement as Acomplia. Millions of obese have eagerly waited for this miracle drug.
The drug is expected to be marketed in the United States, under the name Zimulti. Whatever the trade name, rimonabant has been hailed by some doctors on the basis of clinical trials as a major breakthrough in treating obesity.
The success of Acomplia would depend on the quantum of side effects. The established anti-obesity drugs like Xenical, Meridia (Reductil in Europe), Didrex, and, Phentermine, however, have proven to have troublesome side effects, disappointing millions of dieters.
Email
Print
SPAM
